Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Eagle’s development pipeline features ONS-5010, a biosimilar candidate to ranibizumab (Lucentis®) for ophthalmology, as well as additional early-stage programs targeting rare or critical care indications.
Eagle manufactures its products in North American facilities and leverages strategic partnerships for global distribution and regulatory support. The company has established collaborations with contract development and manufacturing organizations to scale production and has entered licensing agreements to commercialize products in regions outside the United States.
Under its management team, Eagle continues to prioritize streamlined clinical development and efficient regulatory pathways, aiming to strengthen its position in niche hospital-administered markets and expand its offering of injectable therapies for patients with serious or life-threatening conditions.
AI Generated. May Contain Errors.
